These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 20100549)

  • 1. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease.
    Ambrosi G; Armentero MT; Levandis G; Bramanti P; Nappi G; Blandini F
    Brain Res Bull; 2010 Apr; 82(1-2):29-38. PubMed ID: 20100549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease.
    Armentero MT; Fancellu R; Nappi G; Bramanti P; Blandini F
    Neurobiol Dis; 2006 Apr; 22(1):1-9. PubMed ID: 16289868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
    Vernon AC; Zbarsky V; Datla KP; Croucher MJ; Dexter DT
    J Neurochem; 2007 Nov; 103(3):1075-91. PubMed ID: 17714448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist in 6-hydroxydopamine partially lesioned rats reverses abnormal firing of dopaminergic neurons.
    Chen L; Zhang QJ; Liu J; Wang S; Ali U; Gui ZH; Wang Y
    Brain Res; 2009 Aug; 1286():192-200. PubMed ID: 19545547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias.
    Marin C; Bonastre M; Aguilar E; Jiménez A
    Synapse; 2011 Oct; 65(10):1080-6. PubMed ID: 21484883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats.
    Pellegrino D; Cicchetti F; Wang X; Zhu A; Yu M; Saint-Pierre M; Brownell AL
    J Nucl Med; 2007 Jul; 48(7):1147-53. PubMed ID: 17574972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats.
    Alam M; Danysz W; Schmidt WJ; Dekundy A
    Toxicol Appl Pharmacol; 2009 Oct; 240(2):198-207. PubMed ID: 19616571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism.
    Breysse N; Baunez C; Spooren W; Gasparini F; Amalric M
    J Neurosci; 2002 Jul; 22(13):5669-78. PubMed ID: 12097518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats.
    Ferrigno A; Vairetti M; Ambrosi G; Rizzo V; Richelmi P; Blandini F; Fuzzati-Armentero MT
    Clin Exp Pharmacol Physiol; 2015 Jun; 42(6):695-703. PubMed ID: 25904005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of mGluR glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease.
    Phillips JM; Lam HA; Ackerson LC; Maidment NT
    Eur J Neurosci; 2006 Jan; 23(1):151-60. PubMed ID: 16420425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic, systemic treatment with a metabotropic glutamate receptor 5 antagonist produces anxiolytic-like effects and reverses abnormal firing activity of projection neurons in the basolateral nucleus of the amygdala in rats with bilateral 6-OHDA lesions.
    Chen L; Liu J; Ali U; Gui ZH; Hou C; Fan LL; Wang Y; Wang T
    Brain Res Bull; 2011 Feb; 84(3):215-23. PubMed ID: 21255635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats.
    Breysse N; Amalric M; Salin P
    J Neurosci; 2003 Sep; 23(23):8302-9. PubMed ID: 12967992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of chronic, systemic treatment with metabotropic glutamate receptor 5 antagonist on behavioral activity and neuroprotection in a preclinical rat model of Parkinson's disease].
    Chen L; Liu J; Gui ZH; Wang Y; Xiang L
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Jan; 42(1):65-8. PubMed ID: 21355304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of metabotropic glutamate receptor 5 attenuates axonal degeneration in 6-hydroxydopamine-induced model of Parkinson's disease.
    Zhang JN; Huang YL; Yang HM; Wang Y; Gu L; Zhang H
    Mol Cell Neurosci; 2021 Jan; 110():103572. PubMed ID: 33248235
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat.
    Walsh S; Finn DP; Dowd E
    Neuroscience; 2011 Feb; 175():251-61. PubMed ID: 21145947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
    Marin C; Bonastre M; Mengod G; Cortés R; Giralt A; Obeso JA; Schapira AH
    Neurobiol Dis; 2014 Apr; 64():36-47. PubMed ID: 24370700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual target strategy: combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates L-DOPA-induced rotational behavior in a rodent model of Parkinson's disease.
    Fuzzati-Armentero MT; Cerri S; Levandis G; Ambrosi G; Montepeloso E; Antoninetti G; Blandini F; Baqi Y; Müller CE; Volpini R; Costa G; Simola N; Pinna A
    J Neurochem; 2015 Aug; 134(4):740-7. PubMed ID: 25962878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
    Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
    Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabotropic glutamate receptors 5 blockade reverses spatial memory deficits in a mouse model of Parkinson's disease.
    De Leonibus E; Managò F; Giordani F; Petrosino F; Lopez S; Oliverio A; Amalric M; Mele A
    Neuropsychopharmacology; 2009 Feb; 34(3):729-38. PubMed ID: 18704096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model.
    Hsieh MH; Ho SC; Yeh KY; Pawlak CR; Chang HM; Ho YJ; Lai TJ; Wu FY
    Pharmacol Biochem Behav; 2012 Jul; 102(1):64-71. PubMed ID: 22487770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.